T Cell News and Research

Latest T Cell News and Research

Novel therapy for chronic graft-versus-host disease

A study by Dana-Farber Cancer Institute researchers offers the strongest evidence yet of the effectiveness of a novel therapy for chronic graft-versus-host disease (GVHD), a potentially life-threatening complication of donor bone marrow and stem cell transplants.

28 Mar 2006

Study on fruit flies offers new approach to understand human response to viral infections

A research team led by UC Riverside scientists has shown that the common fruit fly can serve as an excellent model for studying the immunity animals are born with for fighting viral infections.

28 Mar 2006

Researchers develop new tool to find gene control regions

Researchers at the McKusick-Nathans Institute of Genetic Medicine at Johns Hopkins have invented a cost-effective and highly efficient way of analyzing what many have termed "junk" DNA and identified regions critical for controlling gene function.

28 Mar 2006

New way of targeting proteins to exosomes - potential for melanoma, Alzheimer's disease

Researchers at the University of Pennsylvania School of Medicine have discovered how a protein called Pmel17 is sorted by pigment cells in the skin and eye to make a fiber matrix that eventually sequesters melanin, the dark pigment found in skin, hair, and eyes.

28 Mar 2006

New information about the molecular pathway used by ubiquitin

Because ubiquitin plays a key role in cell survival, scientists have already begun to develop drugs to target parts of the ubiquitin pathway in treating diseases such as cancer.

28 Mar 2006

Discovery of a gene that drives anthrax bacteria's toxic effects

A study in Cell reports the discovery of a gene that drives anthrax bacteria's toxic effects. The gene could offer a potential new target for countermeasures against the lethal toxin, according to the researchers.

28 Mar 2006

Mustard and garlic kick linked to single pain receptor

A single pain receptor is solely responsible for the kick delivered by mustard oil and garlic, according to research in the Cell. Mustard oil is the active ingredient in mustard and in the pungent green sushi condiment known as wasabi.

28 Mar 2006

RNAi-based inhibitors for created for nearly every human and mouse gene - available to all genetic researchers

An international public-private research team led by scientists at the Broad Institute of MIT and Harvard announced today the construction and availability of an extensive library of molecular reagents to silence most human and mouse genes.

28 Mar 2006

Procedure cures some diabetic mice, but not in the way previously reported

Researchers attempting to reproduce a controversial 2003 mouse experiment suggestive of a cure for type 1 diabetes have found evidence that the experimental procedure does eliminate diabetic symptoms in a small fraction of the mice exposed to it.

28 Mar 2006

Researchers find compound 10 times more effective than isoniazid, the leading anti-tuberculosis drug

Researchers at the Albert Einstein College of Medicine of Yeshiva University have synthesized chemicals that are up to 10 times more effective than isoniazid, the leading anti-tuberculosis drug.

28 Mar 2006

Study provides a boost for efforts to reverse type-1 diabetes

Researchers have been able to confirm most but not all of the results of a high-profile study that brought new hope to diabetes patients. This study provides a boost for efforts to reverse type-1 diabetes in recently diagnosed patients but not for efforts to grow new islets from spleens.

27 Mar 2006

Tobacco plants being used to produce human albumin

Human serum albumin (HSA) is the intravenous protein most commonly used in the world for therapeutic ends. It is employed to stabilise blood volume and to avoid risk of a heart attack, its administration in operating theatres being almost a daily occurrence.

27 Mar 2006

Novel therapy for chronic graft-versus-host disease (GVHD) using Rituximab

Dana-Farber researchers found that rituximab reduced the severity of chronic graft-versus-host disease (GVHD) in 70 percent of the study participants.

27 Mar 2006

Light activated anticancer drug targeted to DNA using cisplatin like sub-units: Coupling light absorbers to reactive metal centers

One of the most effective chemotherapy drugs against cancer is cisplatin because it attaches to cancer DNA and disrupts repair. However, it also kills healthy tissue. Many scientists are creating alternative drugs or cisplatin analogs in attempts to find treatments without side effects.

27 Mar 2006

Innovative sensing tool used to investigate adenosine triposphate release and its role in cystic fibrosis

The ATP study marks the first application of a novel sensing system developed by a research team led by Christine Kranz at the Georgia Institute of Technology.

27 Mar 2006

Evolutionary biology research predicts precancerous tumors

In diverse ecosystems, packed with wildly different species, evolution whizzes along. As different species accumulate mutations, some adapt particularly well to their environment and prosper.

27 Mar 2006

Successful cell engineering may prevent bovine spongiform encephalopathy (BSE)

Researchers at Texas A&M University have successfully "knocked down" the expression of possible disease-causing genes in a cloned goat fetus, perhaps paving the way for breeding disease resistance in other animals, even those genes that might cause bovine spongiform encephalopathy (BSE), commonly known as Mad Cow Disease.

23 Mar 2006

Cell therapy slows progression of metachromatic leukodystrophy

In an important discovery, scientists have demonstrated that the progression of a type of genetic brain disease is slowed and symptoms are improved in mice that received cell transplants.

23 Mar 2006

Phagocytosis depends more on particle shape than size

The research, which has far-reaching implications for immunology, vaccine development and drug delivery, is published today online in the Proceedings of the National Academy of Sciences by Samir Mitragotri, a UCSB professor of chemical engineering, and graduate student Julie A. Champion. The paper will be published in print on March 28.

23 Mar 2006

Trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer

Results from a large, randomised clinical trial for patients with breast cancer show that those who received bevacizumab (Avastin.) in combination with paclitaxel (Taxol.) survived without the disease getting worse for almost twice as long as patients who received paclitaxel alone.

23 Mar 2006